These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 20416137)

  • 1. Moderators and predictors of response to cognitive-behavioral therapy augmentation of pharmacotherapy in obsessive-compulsive disorder.
    Maher MJ; Huppert JD; Chen H; Duan N; Foa EB; Liebowitz MR; Simpson HB
    Psychol Med; 2010 Dec; 40(12):2013-23. PubMed ID: 20416137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?
    Wheaton MG; Rosenfield D; Foa EB; Simpson HB
    J Consult Clin Psychol; 2015 Oct; 83(5):926-937. PubMed ID: 26009783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.
    Simpson HB; Foa EB; Liebowitz MR; Ledley DR; Huppert JD; Cahill S; Vermes D; Schmidt AB; Hembree E; Franklin M; Campeas R; Hahn CG; Petkova E
    Am J Psychiatry; 2008 May; 165(5):621-30. PubMed ID: 18316422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.
    Franklin ME; Sapyta J; Freeman JB; Khanna M; Compton S; Almirall D; Moore P; Choate-Summers M; Garcia A; Edson AL; Foa EB; March JS
    JAMA; 2011 Sep; 306(11):1224-32. PubMed ID: 21934055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in obsessive-compulsive symptoms mediates subsequent change in depressive symptoms during exposure and response prevention.
    Zandberg LJ; Zang Y; McLean CP; Yeh R; Simpson HB; Foa EB
    Behav Res Ther; 2015 May; 68():76-81. PubMed ID: 25824533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.
    Foa EB; Simpson HB; Rosenfield D; Liebowitz MR; Cahill SP; Huppert JD; Bender J; McLean CP; Maher MJ; Campeas R; Hahn CG; Imms P; Pinto A; Powers MB; Rodriguez CI; Van Meter PE; Vermes D; Williams MT
    J Clin Psychiatry; 2015 Apr; 76(4):440-6. PubMed ID: 25375780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin reuptake inhibitor-cognitive behavioural therapy-second generation antipsychotic combination for severe treatment-resistant obsessive-compulsive disorder. A prospective observational study.
    Tundo A; Salvati L; Cieri L; Balestrini V; Di Spigno D; Orazi F; Iommi M; Necci R
    Int J Psychiatry Clin Pract; 2022 Nov; 26(4):395-400. PubMed ID: 35323098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial.
    Foa EB; Simpson HB; Gallagher T; Wheaton MG; Gershkovich M; Schmidt AB; Huppert JD; Imms P; Campeas RB; Cahill S; DiChiara C; Tsao SD; Puliafico A; Chazin D; Asnaani A; Moore K; Tyler J; Steinman SA; Sanches-LaCay A; Capaldi S; Snorrason Í; Turk-Karan E; Vermes D; Kalanthroff E; Pinto A; Hamlett GE; Middleton R; Hahn CG; Xu B; Van Meter PE; Katechis M; Rosenfield D
    JAMA Psychiatry; 2022 Mar; 79(3):193-200. PubMed ID: 35080598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A META-ANALYSIS OF COGNITIVE BEHAVIOR THERAPY AND MEDICATION FOR CHILD OBSESSIVE-COMPULSIVE DISORDER: MODERATORS OF TREATMENT EFFICACY, RESPONSE, AND REMISSION.
    McGuire JF; Piacentini J; Lewin AB; Brennan EA; Murphy TK; Storch EA
    Depress Anxiety; 2015 Aug; 32(8):580-93. PubMed ID: 26130211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral avoidance predicts treatment outcome with exposure and response prevention for obsessive-compulsive disorder.
    Wheaton MG; Gershkovich M; Gallagher T; Foa EB; Simpson HB
    Depress Anxiety; 2018 Mar; 35(3):256-263. PubMed ID: 29394511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximizing remission from cognitive-behavioral therapy in medicated adults with obsessive-compulsive disorder.
    Simpson HB; Foa EB; Wheaton MG; Gallagher T; Gershkovich M; Schmidt AB; Huppert JD; Campeas RB; Imms PA; Cahill SP; DiChiara C; Tsao SD; Puliafico AC; Chazin D; Asnaani A; Moore K; Tyler J; Steinman SA; Sanchez-LaCay A; Capaldi S; Snorrason I; Turk-Karan E; Vermes D; Kalanthroff E; Pinto A; Hahn CG; Xu B; Van Meter PE; Katechis M; Scodes J; Wang Y
    Behav Res Ther; 2021 Aug; 143():103890. PubMed ID: 34089924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary outcomes from the pediatric obsessive compulsive disorder treatment study II.
    Conelea CA; Selles RR; Benito KG; Walther MM; Machan JT; Garcia AM; Sapyta J; Morris S; Franklin M; Freeman JB
    J Psychiatr Res; 2017 Sep; 92():94-100. PubMed ID: 28412602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.
    McLean CP; Zandberg LJ; Van Meter PE; Carpenter JK; Simpson HB; Foa EB
    J Clin Psychiatry; 2015 Dec; 76(12):1653-7. PubMed ID: 26613263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of clinical worsening during a discontinuation trial of serotonin reuptake inhibitors for obsessive compulsive disorder.
    Tyler J; Gallagher T; Wheaton MG; Hamlett GE; Rosenfield B; Rosenfield D; Simpson HB; Foa EB
    J Anxiety Disord; 2024 Jan; 101():102805. PubMed ID: 38113781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors associated with improved cognitive-behavioral therapy outcome in pediatric obsessive-compulsive disorder.
    Torp NC; Dahl K; Skarphedinsson G; Compton S; Thomsen PH; Weidle B; Hybel K; Valderhaug R; Melin K; Nissen JB; Ivarsson T
    J Am Acad Child Adolesc Psychiatry; 2015 Mar; 54(3):200-207.e1. PubMed ID: 25721185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder.
    Simpson HB; Liebowitz MR; Foa EB; Kozak MJ; Schmidt AB; Rowan V; Petkova E; Kjernisted K; Huppert JD; Franklin ME; Davies SO; Campeas R
    Depress Anxiety; 2004; 19(4):225-33. PubMed ID: 15274171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of treatment on quality of life and functioning in OCD.
    Asnaani A; Kaczkurkin AN; Alpert E; McLean CP; Simpson HB; Foa EB
    Compr Psychiatry; 2017 Feb; 73():7-14. PubMed ID: 27838572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive behavioral and pharmacological treatments of OCD in children: A systematic review and meta-analysis.
    Öst LG; Riise EN; Wergeland GJ; Hansen B; Kvale G
    J Anxiety Disord; 2016 Oct; 43():58-69. PubMed ID: 27632568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.